A Phase III Randomized Double Blind Placebo Controlled Trial of CM-AT in Children With Autism.
Phase of Trial: Phase III
Latest Information Update: 21 Apr 2018
At a glance
- Drugs CM 4612 (Primary)
- Indications Autistic disorder
- Focus Registrational; Therapeutic Use
- 04 Nov 2013 Curemark submitted an NDA for CM 4612 to the US FDA.
- 06 Aug 2012 FDA approves direct enrolment into an open label extension. Not sure how this relates to the extension info that was already in here
- 30 Sep 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov (Parent trial: NCT00881452).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History